Menu
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, recently joined the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of care.
SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that are helping to progress oncology research and tumor mutation profiling. Liquid biopsy offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma. This testing approach allows for non-invasive cancer genomic profiling and disease monitoring, revealing critical insights in cases where tissue biopsy may not be feasible. However, liquid biopsy still faces challenges, including workflow standardization and broad adoption across the globe.
Building on the momentum of the recent launch of MSK-ACCESS® powered with SOPHiA DDM™ earlier this year, we would like to develop a community of knowledge, where peers can connect, share experiences, and hear the latest updates regarding the implementation of decentralized Memorial Sloan Kettering Cancer Center (MSK) applications.
In this webinar, attendees will:
➡️ Learn more about Memorial Sloan Kettering Cancer Center’s and
SOPHiA GENETICS’s strategies to lower liquid biopsy hurdles.
➡️ Learn more about the evolution of MSK-ACCESS® assay.
➡️ Hear about the evidence-generation efforts to demonstrate the clinical utility of MSK-ACCESS® powered with SOPHiA DDM™
➡️ Gain insights into new analytical performance data from early adopters across Europe
➡️ Get the latest updates and discuss our initiative to facilitate sample sharing among centers
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
